VBL to present Data from Phase 2 trial of VB-111 at SNO annual meet

	The company will present a study of neoadjuvant and adjuvant VB-111 for treatment of recurrent GBM.
	The ongoing trial aims to explore the potential of VB-111 in treating rGBM.


VBL Therapeutics, a late-stage clinical biopharmaceutical company focused on the development of cancer treatments, has reportedly announced that it will present the data on the new investigator-sponsored Phase 2 clinical study of VB-111 in rGBM (recurrent glioblastoma) at 2019 Society for Neuro-Oncology (SNO) annual meeting, held between Nov. 20-24 in Phoenix, Arizona.

Reportedly, Timothy Cloughesy, M.D., Professor and Director, UCLA Neuro-Oncology Program will present data from this clinical study.

According to reports, the controlled, randomized clinical trial would evaluate VB-111 in rGBM patients who are undergoing a second surgery. The drug candidate will be dosed either before as well as after the surgery or just after the surgery and will be compared to the third cohort which will receive standard care as control.  

The primary endpoint of this new clinal trail is an immunological readout. The endpoint is to investigate if VB-111 administration before the surgery can increase in TIL (tumor infiltrating T lymphocyte) in the rGBM tumor. The secondary endpoint includes PFS-6 (progression-free survival for six months) and OS (overall survival). The company has enrolled 45 patients that would be randomized across three groups. 

Dr. Cloughesy, the study’s co-principal investigator, stated that the MRI analysis of VB-111 Phase 2 and GLOBE Phase 3 studies conducted at UCLA showed objective responses to VB-111 monotherapy. Cloughesy further added that this positive finding recommend that there is a need to further explore the potential of VB-111 in rGBM.

Speaking on clinical trial Vice President Clinical Development at VBL Therapeutics, Tami Rachmilewitz, M.D., stated that this study would provide more information on the therapeutic potential of VB-111 when administrated as monotherapy. The study is purposely designed as a controlled, randomized, blinded clinical trial to generate results that would come under a future filing with regulatory authorities. 

Addressing opinion leaders in the glioblastoma field, Rachmilewitz thanked them for pursuing the potential benefits of VB-111 in treating this deadly disease.

Source Credit - https://finance.yahoo.com/news/vbl-therapeutics-present-data-investigator-130000575.html